This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
I always found science fascinating, but I really fell in love with it in high school when I was introduced to biochemistry and molecularbiology. Biochemistry and molecularbiology fascinated me in school. Can you tell us about your journey in the field of STEM and the challenges you encountered along the way?
Advancements in cell line development (CLD), including screening and selection of final clones, scale up, automation and digitalisation have enabled precision and enhanced productivity. Efforts have focused on Chinese hamster ovary (CHO) cell line improvements since it is a commonly used host for the expression of therapeutic proteins.
Secondly, circRNAs can be engineered for more efficient proteinexpression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in proteinexpression and durability have been demonstrated by the circVec 2.1
The deal will provide Biogen the rights to use the technology across their portfolio of gene therapy products. This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. based Mogrify Limited expanded its research collaboration with MRC Laboratory of MolecularBiology.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content